Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDDIA: Dapagliflozin for Diastolic Dysfunction in T2DM
NCT02751398Phase 4Completed
- Sponsor
- Yonsei University
- Start
- Aug 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Subclinical diastolic dysfunction assessed by supine bicycle diastolic stress echocardiography at 24 weeks. Started Aug 2016; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02751398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02751398.